We enhance lives by utilizing transformational scientific platforms that enable best-in-class genetic therapies.

Scriptr was established in 2019 by Keith Alkek and Dr. Douglas Anderson with the vision of developing a company proficient in designing numerous therapeutics based on innovative DNA and RNA platform technologies. Since its inception, Scriptr has advanced various scientific innovations, including a novel method to efficiently ligate RNA that leaves no scar on the RNA. This technology has the potential to facilitate the development of numerous therapeutics in both gene therapy and circular RNA therapeutics. Scriptr is committed to being responsible stewards of platform technologies with broad applications and believes that collaborating with others is essential to fostering the creation and commercialization of many therapeutics, ultimately improving countless lives.

Vision

To be recognized as a trusted leader in advancing therapeutics through collaborative partnerships.

Goals

  • Develop and advance transformational platform technologies.
  • Establish expertise in advancing therapeutics through collaborative business development.
  • Maintain teams of inspired and passionate individuals.
  • Foster positive outcomes.

Values

At Scriptr, we are firmly dedicated to two fundamental principles: leveraging high-quality genetic science to tackle health challenges and promoting collaboration to maximize benefits for humanity.

This is the essence of our commitment encapsulated in "Genetic Solutions for Good".